Abstract

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Hervé Tiriac, Associate Project Scientist, University of California-San Diego

New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for pancreatic cancer patients. Combined genomic, transcriptomic, and therapeutic profiling of patient-derived organoids can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses and facilitate precision medicine for pancreatic cancer patients.